MedPath

Internet-Based Exposure Therapy Vs. Stress-Management Training for Worry

Not Applicable
Completed
Conditions
Excessive Worry
Registration Number
NCT02638792
Lead Sponsor
Karolinska Institutet
Brief Summary

The purpose of this study is to examine if an internet-based exposure therapy is more effective in reducing excessive worry amongst patients who suffer from this problem than is internet-based stress management training.

Detailed Description

Trial Objectives: Primary objective is to investigate whether an Internet-based exposure therapy can reduce the degree of excessive worry to a significantly greater extent than Internet-based stress-management training. The secondary objective is to a) investigate the cost-effectiveness of this treatment b) to study if any variables could moderate/mediate the treatment outcome, c) and to investigate the importance of sudden gains for the treatment outcome

Trial Design: Randomized controlled trial with an active control and a waitlist control, who also will recieve treatment after the first group has finished.

Duration: Ten weeks

Primary Endpoint:

Difference in worry symptoms between the treatment groups at week 10. Long term follow-up is also investigated (baseline to 4-months after treatment completion and baseline to 12-months after treatment completion).

Efficacy Parameters: Penn State Worry Questionnaire (PSWQ)

Safety Parameters: Adverse Events is assessed via the internet.

Description of Trial Subjects: Patients \> 18 years old with a PSWQ score more than 56 points

Number of Subjects: 300

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
311
Inclusion Criteria
  • Outpatients
  • ≥ 18 years
  • Situated in Sweden
  • Informed consent
  • PSWQ score more than 56 points
Exclusion Criteria
  • Substance dependence during the last six months
  • Post traumatic stress disorder, bipolar disorder or psychosis
  • Symptoms better explained by axis 2 diagnosis (e.g. autism or borderline personality disorder)
  • MADRS-S score above 25 points
  • Psychotropic medication changes within two months prior to treatment that could affect target symptoms.
  • Received exposure based CBT for pathological worry the last 2 years.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Penn State Worry Questionnaire (PSWQ)week 0, week 10 (weekly measurements), at 4 months follow up, 12 months follow up.

Change in worry from baseline to Week 10 and at 4- and 12 months after treatment has ended.

Secondary Outcome Measures
NameTimeMethod
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)Week 0, Week 10, 4 and 12 months follow-up

Change in economic costs from baseline to Week 10 and at 4- and 12 months after treatment has ended

Thought supression subscale of the Cognitive Avoidance Questionnaire (CAQ)Week 0 - Week 10 (weekly measurements)

Weekly change in thought supression from baseline to Week 10

The self-regulation subscale of the Multidimensional Assessment of Interoceptive AwarenessWeek 0 - Week 10 (weekly measurements)

Weekly change in self-regulation from baseline to Week 10

Euroqol, EQ-5DWeek 0, Week 10, 4 and 12 months follow-up

Change in general health from baseline to Week 10 and at 4- and 12 months after treatment has ended

Intolerance of uncertainty scaleWeek 0, Week 10, at 4 and 12 months follow-up, and weekly during treatment

Change in thought control efforts from baseline to Week 10, at 4- and 12 months after treatment has ended, and weekly during treatment

Brunnsviken Quality of Life Questionnaire (BBQ)Week 0, Week 10, 4 and 12 months follow-up

Change in self-perceived quality of life from baseline to week 10 and at 4 and 12 months after treatment has ended

Patient Health Questionnaire-2Week 0 - Week 10 (weekly measurements)

Weekly change in depressive symptom from baseline to Week 10

Adverse EventsWeek 3, week 8, week 10, 4 and 12 months follow-up

Number of adverse events from baseline to Week 10 and at 4 and 12 months

Montgomery Åsberg Depression Rating Scale (MADRS-S)Week 0, Week 10, 4 and 12 months follow-up

Change in depression from baseline to Week 10 and at 4- and 12 months after treatment has ended.

Cognitive Avoidance Questionnaire (CAQ)Week 0, Week 10, at 4 and 12 months follow up and weekly during treatment

Change in cognitive avoidance from baseline to Week 10, at 4- and 12 after treatment has ended, and weekly during treatment

Trial Locations

Locations (1)

Karolinska Intitutet

🇸🇪

Stockholm, Sweden

Karolinska Intitutet
🇸🇪Stockholm, Sweden

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.